|
Immutep Limited (IMMP): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Immutep Limited (IMMP) Bundle
Immutep Limited (IMMP) stands at the forefront of revolutionary immunotherapeutic research, transforming the landscape of cancer and autoimmune disease treatment through cutting-edge scientific innovation. By leveraging its unique LAG-3 related therapeutic platform, this Australian-based biopharmaceutical company is pioneering breakthrough approaches that could potentially reshape global medical interventions, offering hope to patients worldwide through advanced clinical-stage drug development and strategic international partnerships.
Immutep Limited (IMMP) - Marketing Mix: Product
Biopharmaceutical Company Profile
Immutep Limited is a clinical-stage biotechnology company specializing in immunotherapy treatments, with a primary focus on LAG-3 related therapeutic candidates.
Product Portfolio
| Product | Therapeutic Area | Development Stage |
|---|---|---|
| Eftilagimod alpha (IMP321) | Metastatic Breast Cancer | Phase 3 Clinical Trial |
| IMP761 | Autoimmune Diseases | Preclinical Stage |
| IMP701 | Oncology | Early Clinical Development |
Key Product Characteristics
- Innovative immunotherapy platform targeting lymphocyte activation
- Focus on LAG-3 protein mechanism
- Potential applications in cancer and autoimmune treatments
Research and Development Focus
Immutep concentrates on developing immunotherapeutic drugs with potential global application in two primary research areas:
- Oncology
- Autoimmune Disease Treatment
Clinical Development Pipeline
| Program | Indication | Current Status |
|---|---|---|
| AIPAC Study | Metastatic Breast Cancer | Ongoing Phase 3 Trial |
| TACTI-002 Study | Solid Tumors | Phase 2 Clinical Trial |
Technological Platform
LAG-3 (Lymphocyte-activation gene 3) represents the core technological platform for Immutep's product development strategy.
Immutep Limited (IMMP) - Marketing Mix: Place
Headquarters and Global Operations
Headquartered at Level 12, 95 Pitt Street, Sydney, NSW 2000, Australia.
Global Research and Development Locations
| Location | Type of Operations |
|---|---|
| Sydney, Australia | Primary Headquarters |
| Paris, France | European Research Center |
| United States | Clinical Trial Coordination |
Clinical Trial Locations
- United States
- Europe (Multiple Countries)
- Australia
Strategic Market Presence
Key Pharmaceutical Markets:
- United States
- European Union
- Australia
Distribution Partnerships
| Partner | Region | Partnership Focus |
|---|---|---|
| Merck KGaA | Global | LAG-3 technology licensing |
| Novartis | United States | Clinical development |
Market Access Strategy
Distribution Channels:
- Direct pharmaceutical partnerships
- Clinical trial networks
- Biotechnology research collaborations
Immutep Limited (IMMP) - Marketing Mix: Promotion
Presenting at Key Scientific and Medical Conferences
Immutep Limited actively participates in the following key conferences:
| Conference Name | Date | Location | Presentation Focus |
|---|---|---|---|
| American Association for Cancer Research (AACR) | April 2024 | San Diego, CA | LAG-3 immunotherapy research |
| European Society for Medical Oncology (ESMO) | September 2024 | Madrid, Spain | Clinical trial results |
Engaging Investor Relations Through Financial Presentations
Investor communication activities include:
- Quarterly earnings webcast
- Annual shareholder meeting
- Investor conference presentations
| Investor Event | Frequency | Participation Rate |
|---|---|---|
| Quarterly Earnings Call | 4 times per year | Approximately 75 institutional investors |
| Biotechnology Investor Conference | 2 times per year | Over 100 potential investors |
Publishing Research Findings in Peer-Reviewed Medical Journals
Publication details for 2024:
| Journal | Number of Publications | Impact Factor |
|---|---|---|
| Nature Medicine | 2 publications | 53.4 |
| Journal of Clinical Oncology | 3 publications | 41.2 |
Utilizing Digital Platforms for Scientific and Investor Communications
Digital communication channels:
- LinkedIn followers: 15,000
- Twitter followers: 8,500
- Corporate website monthly visitors: 50,000
Participating in Biotechnology Industry Networking Events
| Event | Networking Opportunities | Potential Collaborations |
|---|---|---|
| Biotechnology Innovation Organization (BIO) Convention | 250+ industry contacts | 5 potential research partnerships |
| JP Morgan Healthcare Conference | 150+ investor meetings | 3 potential funding discussions |
Immutep Limited (IMMP) - Marketing Mix: Price
Current Revenue Status
As of 2024, Immutep Limited has no commercial product revenue generated from therapeutic products.
Funding Mechanisms
The company's financial strategy involves multiple funding channels:
- Research and development funded through strategic partnerships
- Capital raising through equity financing
- Investor funding mechanisms
Financial Performance Metrics
| Financial Metric | Value | Year |
|---|---|---|
| Market Capitalization | AUD 172.43 million | 2024 |
| Stock Price (ASX) | AUD 0.38 per share | January 2024 |
| Cash Reserves | AUD 36.2 million | December 2023 |
Stock Trading Details
Traded on Australian Securities Exchange (ASX) under ticker symbol IMMP.
Valuation Drivers
- Potential of therapeutic pipeline
- Research and development progress
- Clinical trial advancement
Investor Funding Breakdown
| Funding Source | Amount | Year |
|---|---|---|
| Equity Raise | AUD 45.6 million | 2023 |
| Research Grants | AUD 3.2 million | 2023 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.